UNSPSC 51171521: Calcarea silicata

This classification denotes an industrial aid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S4255P4G5M. European Medicines Agency schedules Calcium silicate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12473MIG. Calcium silicate generally arises in the molecular formula CA.H2O3SI. The term 'calcium silicate' is a United States Homeopathic Pharmacopoeia Name designation. SMILES: [Ca].[Ca].[Si](O)(O)(O)O.

UNSPSC 51171521 Calcarea silicata is a Commodity code that covers calcium silicate products used in laboratory and clinical testing applications. Recent state and local solicitations under this code do not reflect direct procurement of calcarea silicata itself; instead, the tagged opportunities involve pharmaceutical and drug-testing services where calcium silicate may appear as a component in specimen collection, immunoassay screening, or laboratory certification workflows. The issuing bodies seeking these services span county criminal-justice departments, state health agencies, and multistate cooperative purchasing alliances. Collin County Community Supervision and Corrections Department issued an RFP (2026-327, due July 23, 2026) for offender specimen collection and drug testing services, requesting vendors capable of operating collection sites, screening and confirmation testing via immunoassay with LC/MS/MS or GC/MS confirmation, and maintaining SAMHSA or state lab certification. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities in Minnesota and Oregon. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in late March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, a preliminary market-intelligence phase preceding formal procurement.

The code shows limited direct activity specific to calcarea silicata procurement and instead appears to be a taxonomy mismatch for the posted opportunities, which center on pharmaceutical distribution, drug testing services, and pharmacy benefit administration rather than industrial or laboratory-grade calcium silicate materials. Geographic activity is concentrated in Texas (Collin County and HHS) and Minnesota (MMCAP, serving Minnesota and Oregon). The representative opportunities reflect broader state and local interest in clinical laboratory services, pharmaceutical supply chains, and specimen-handling workflows, but not direct sourcing of calcarea silicata as a standalone product. Firms pursuing business under this code should clarify whether their calcium silicate products serve laboratory certification, specimen-collection, or pharmaceutical-manufacturing workflows specific to state and local health, corrections, or benefit-administration programs.